Sex Differences in Survival from Neuroendocrine Neoplasia in England 2012 & 2018: A Retrospective, Population-Based Study : published 20th March 2023.
A retrospective, population-based study comparing overall survival (OS) between males and females with neuroendocrine neoplasia (NEN).
In total, 14,834 cases of NEN recorded in England’s National Cancer Registry and Analysis Service (NCRAS)), were analysed. Females displayed increased survival irrespective of the stage, morphology or level of deprivation, which was statistically significant in NEN of the lung, pancreas, rectum and stomach. Stage of tumour mediated improved survival in stomach, lung, and pancreatic NEN but not in rectal NEN.
Females diagnosed with NEN tend to survive longer than males, and stage at presentation only accounts for part of this effect.
Future research in NEN, as well as prognostication and treatment, should consider sex as an important factor.
Cancers 2023, 15(6), 1863; https://doi.org/10.3390/cancers15061863
The authors would like to thank NHS Digital and The National Cancer Registration and Analysis Service for providing us with the registry data for analysis. This work uses data provided by patients and collected by the NHS as part of their care and support.
They would also like to thank Hampshire Hospitals NHS Foundation Trust for sponsoring the study and Neuroendocrine Cancer UK for providing funding (grant).